<ul>
	<li>Hemorrhage: Permanently discontinue regorafenib for severe or life-threatening hemorrhage.</li>
	<li>Dermatological toxicity: Interrupt and then reduce or discontinue regorafenib depending on severity and persistence of dermatologic toxicity.</li>
	<li>Hypertension: Temporarily or permanently discontinue regorafenib for severe or uncontrolled hypertension.</li>
	<li>Cardiac ischemia and infarction: Withhold regorafenib for new or acute cardiac ischemia/infarction and resume only after resolution of acute ischemic events.</li>
	<li>Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Discontinue regorafenib.</li>
	<li>Gastrointestinal perforation or fistulae: Discontinue regorafenib.</li>
	<li>Wound healing complications: Stop regorafenib before surgery. Discontinue in patients with wound dehiscence.</li>
	<li>Embryofetal toxicity: Can cause fetal harm. Advise women of potential risk to a fetus.</li>
</ul>